News
ANTX
15.49
0.00%
0.00
AN2 Therapeutics Announces Results From Two Studies Evaluating Its Oral CPSF3 Inhibitor, AN2-502998, For The Treatment Of Chronic Chagas Disease; Parasites Eliminated With 28-Day Treatment In 100% Of Nonhuman Primates
Benzinga · 06/04 11:16
AN2 Therapeutics Announces Results From Two Studies Evaluating Oral CPSF3 Inhibitor, AN2-502998, For Treatment Of Chronic Chagas Disease Caused By Infection With Parasite T. Cruzi
Benzinga · 06/04 11:09
AN2 Therapeutics Price Target Announced at $9.00/Share by Leerink Partners
Dow Jones · 05/14 20:45
AN2 Therapeutics Raised to Outperform From Market Perform by Leerink Partners
Dow Jones · 05/14 20:45
Leerink Partners Upgrades AN2 Therapeutics to Outperform, Announces $9 Price Target
Benzinga · 05/14 20:35
AN2 Therapeutics Enters Open Market Sale Agreement With Jefferies Dated April 9, 2026; Co. May Offer And Sell Common Stock Up To $80M Through Jefferies
Benzinga · 04/20 20:40
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 04/17 12:05
AN2 Therapeutics Files Prospectus To Offer And Sell Up To $300M Of Securities
Benzinga · 04/09 21:32
AN2 Therapeutics Enters Open Market Sale Agreement With Jefferies; Co. May Issue And Sell From Time To Time Up To An Aggregate Of $80M Of Shares Of The Company's Common Stock
Benzinga · 04/09 21:11
AN2 Therapeutics Initiates Phase 2 Trial Of leucyl-tRNA Synthetase (LeuRS) Mycobacterium Abscessus, With Topline Data Planned For Late 2027
Benzinga · 03/31 11:07
*AN2 Therapeutics: March 2026 Private Placement Extends Runway Into 2029 >ANTX
Dow Jones · 03/17 20:17
*AN2 Therapeutics On Track to Advance Two Boron-Based Oncology Compounds Into Development in 2026 >ANTX
Dow Jones · 03/17 20:17
AN2 Therapeutics Q4 EPS $(0.29) Misses $(0.24) Estimate
Benzinga · 03/17 20:07
Press Release: AN2 Therapeutics Reports Fourth -2-
Dow Jones · 03/17 20:00
*AN2 Therapeutics 4Q Loss $8.71M >ANTX
Dow Jones · 03/17 20:00
Press Release: AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights
Dow Jones · 03/17 20:00
*AN2 Therapeutics 4Q Loss/Shr 29c >ANTX
Dow Jones · 03/17 20:00
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 03/11 17:06
AN2 Therapeutics Stock Cools Off After 90% Rally
Benzinga · 03/11 13:52
AN2 Therapeutics Stock Jumps 90% Monday: What's Driving The Action?
Benzinga · 03/09 18:49
More
Webull provides a variety of real-time ANTX stock news. You can receive the latest news about Anthem through multiple platforms. This information may help you make smarter investment decisions.
About ANTX
Anthem, Inc. is a health benefits company. The Company operates through three segments: Commercial and Specialty Business, Government Business and Other. It offers a spectrum of network-based managed care plans to large and small employer, individual, Medicaid and Medicare markets. Its managed care plans include preferred provider organizations; health maintenance organizations; point-of-service plans; indemnity plans and other hybrid plans, including consumer-driven health plans; and hospital only and limited benefit products. It also provides an array of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs and other administrative services. It provides an array of specialty and other insurance products and services, such as dental, vision, life and disability insurance benefits and radiology benefit management.